nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—chronic obstructive pulmonary disease	0.474	1	CbGaD
Valsartan—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0757	0.283	CbGbCtD
Valsartan—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0757	0.283	CbGbCtD
Valsartan—ALB—Prednisone—chronic obstructive pulmonary disease	0.059	0.22	CbGbCtD
Valsartan—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0574	0.214	CbGbCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.00202	0.0499	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of organic anions—ALB—chronic obstructive pulmonary disease	0.00122	0.03	CbGpPWpGaD
Valsartan—Irbesartan—CYP1A2—chronic obstructive pulmonary disease	0.0012	0.342	CrCbGaD
Valsartan—Losartan—ACE—chronic obstructive pulmonary disease	0.00109	0.311	CrCbGaD
Valsartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.000998	0.0246	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—ADRB2—chronic obstructive pulmonary disease	0.000969	0.0239	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.00094	0.0232	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.000926	0.0229	CbGpPWpGaD
Valsartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.000908	0.0224	CbGpPWpGaD
Valsartan—SLCO1B3—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.000901	0.0222	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.000849	0.021	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of organic anions—ALB—chronic obstructive pulmonary disease	0.000817	0.0202	CbGpPWpGaD
Valsartan—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.000771	0.22	CrCbGaD
Valsartan—AGTR1—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.000766	0.0189	CbGpPWpGaD
Valsartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000725	0.0179	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000714	0.0176	CbGpPWpGaD
Valsartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00066	0.0163	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000657	0.0162	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000622	0.0154	CbGpPWpGaD
Valsartan—SLCO1B1—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.000605	0.0149	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—SOD3—chronic obstructive pulmonary disease	0.000505	0.0125	CbGpPWpGaD
Valsartan—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000497	0.00232	CcSEcCtD
Valsartan—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000496	0.00232	CcSEcCtD
Valsartan—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000493	0.0023	CcSEcCtD
Valsartan—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000491	0.0023	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000491	0.00229	CcSEcCtD
Valsartan—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000487	0.00228	CcSEcCtD
Valsartan—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00228	CcSEcCtD
Valsartan—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00228	CcSEcCtD
Valsartan—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000487	0.00227	CcSEcCtD
Valsartan—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000484	0.00226	CcSEcCtD
Valsartan—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000484	0.00226	CcSEcCtD
Valsartan—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000479	0.0118	CbGpPWpGaD
Valsartan—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000477	0.00223	CcSEcCtD
Valsartan—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000474	0.00222	CcSEcCtD
Valsartan—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000471	0.0022	CcSEcCtD
Valsartan—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000471	0.0022	CcSEcCtD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.000471	0.0116	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000467	0.00218	CcSEcCtD
Valsartan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000465	0.00217	CcSEcCtD
Valsartan—Cough—Formoterol—chronic obstructive pulmonary disease	0.000465	0.00217	CcSEcCtD
Valsartan—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000465	0.00217	CcSEcCtD
Valsartan—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000461	0.00216	CcSEcCtD
Valsartan—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000461	0.0114	CbGpPWpGaD
Valsartan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000461	0.00215	CcSEcCtD
Valsartan—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00215	CcSEcCtD
Valsartan—Cough—Montelukast—chronic obstructive pulmonary disease	0.000455	0.00213	CcSEcCtD
Valsartan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00212	CcSEcCtD
Valsartan—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00211	CcSEcCtD
Valsartan—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00211	CcSEcCtD
Valsartan—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00211	CcSEcCtD
Valsartan—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000452	0.00211	CcSEcCtD
Valsartan—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000451	0.00211	CcSEcCtD
Valsartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—chronic obstructive pulmonary disease	0.000451	0.0111	CbGpPWpGaD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00045	0.00211	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00045	0.00211	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000446	0.011	CbGpPWpGaD
Valsartan—Losartan—ALB—chronic obstructive pulmonary disease	0.000445	0.127	CrCbGaD
Valsartan—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.00208	CcSEcCtD
Valsartan—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000444	0.00208	CcSEcCtD
Valsartan—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000444	0.00208	CcSEcCtD
Valsartan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000444	0.00207	CcSEcCtD
Valsartan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000444	0.00207	CcSEcCtD
Valsartan—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000443	0.00207	CcSEcCtD
Valsartan—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000442	0.00207	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000441	0.00206	CcSEcCtD
Valsartan—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000441	0.00206	CcSEcCtD
Valsartan—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000439	0.00205	CcSEcCtD
Valsartan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00203	CcSEcCtD
Valsartan—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00203	CcSEcCtD
Valsartan—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00203	CcSEcCtD
Valsartan—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00203	CcSEcCtD
Valsartan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000432	0.00202	CcSEcCtD
Valsartan—Infection—Formoterol—chronic obstructive pulmonary disease	0.000432	0.00202	CcSEcCtD
Valsartan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.002	CcSEcCtD
Valsartan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.002	CcSEcCtD
Valsartan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.002	CcSEcCtD
Valsartan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000428	0.002	CcSEcCtD
Valsartan—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.002	CcSEcCtD
Valsartan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00199	CcSEcCtD
Valsartan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00199	CcSEcCtD
Valsartan—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000426	0.00199	CcSEcCtD
Valsartan—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000426	0.00199	CcSEcCtD
Valsartan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000426	0.00199	CcSEcCtD
Valsartan—Infection—Montelukast—chronic obstructive pulmonary disease	0.000423	0.00198	CcSEcCtD
Valsartan—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.00198	CcSEcCtD
Valsartan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000422	0.00197	CcSEcCtD
Valsartan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000422	0.00197	CcSEcCtD
Valsartan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000421	0.00197	CcSEcCtD
Valsartan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000419	0.00196	CcSEcCtD
Valsartan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00195	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000418	0.0103	CbGpPWpGaD
Valsartan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000417	0.00195	CcSEcCtD
Valsartan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000414	0.00193	CcSEcCtD
Valsartan—ALB—Folate Metabolism—SOD3—chronic obstructive pulmonary disease	0.000411	0.0102	CbGpPWpGaD
Valsartan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00192	CcSEcCtD
Valsartan—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00192	CcSEcCtD
Valsartan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000408	0.00191	CcSEcCtD
Valsartan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000406	0.0019	CcSEcCtD
Valsartan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000406	0.0019	CcSEcCtD
Valsartan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000404	0.00189	CcSEcCtD
Valsartan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000404	0.00189	CcSEcCtD
Valsartan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00188	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000399	0.00986	CbGpPWpGaD
Valsartan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00186	CcSEcCtD
Valsartan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000397	0.00186	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—chronic obstructive pulmonary disease	0.000397	0.0098	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000396	0.00185	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000396	0.00185	CcSEcCtD
Valsartan—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00184	CcSEcCtD
Valsartan—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00184	CcSEcCtD
Valsartan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00183	CcSEcCtD
Valsartan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000391	0.00183	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00181	CcSEcCtD
Valsartan—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000388	0.00181	CcSEcCtD
Valsartan—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000388	0.00181	CcSEcCtD
Valsartan—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000387	0.00181	CcSEcCtD
Valsartan—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000387	0.00181	CcSEcCtD
Valsartan—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000385	0.0018	CcSEcCtD
Valsartan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00179	CcSEcCtD
Valsartan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000383	0.00179	CcSEcCtD
Valsartan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000383	0.00179	CcSEcCtD
Valsartan—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00179	CcSEcCtD
Valsartan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000381	0.00178	CcSEcCtD
Valsartan—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000379	0.00177	CcSEcCtD
Valsartan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00177	CcSEcCtD
Valsartan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00175	CcSEcCtD
Valsartan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00175	CcSEcCtD
Valsartan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00175	CcSEcCtD
Valsartan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00175	CcSEcCtD
Valsartan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00175	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00175	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000372	0.00919	CbGpPWpGaD
Valsartan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00174	CcSEcCtD
Valsartan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00174	CcSEcCtD
Valsartan—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.00174	CcSEcCtD
Valsartan—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.00172	CcSEcCtD
Valsartan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000368	0.00172	CcSEcCtD
Valsartan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000367	0.00172	CcSEcCtD
Valsartan—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000366	0.00171	CcSEcCtD
Valsartan—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000365	0.00171	CcSEcCtD
Valsartan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.0017	CcSEcCtD
Valsartan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00169	CcSEcCtD
Valsartan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00036	0.00168	CcSEcCtD
Valsartan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00036	0.00168	CcSEcCtD
Valsartan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000358	0.00167	CcSEcCtD
Valsartan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000357	0.00167	CcSEcCtD
Valsartan—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000357	0.00167	CcSEcCtD
Valsartan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00167	CcSEcCtD
Valsartan—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00166	CcSEcCtD
Valsartan—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00166	CcSEcCtD
Valsartan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00166	CcSEcCtD
Valsartan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00165	CcSEcCtD
Valsartan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00164	CcSEcCtD
Valsartan—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000348	0.00163	CcSEcCtD
Valsartan—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000348	0.0086	CbGpPWpGaD
Valsartan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00161	CcSEcCtD
Valsartan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00161	CcSEcCtD
Valsartan—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000344	0.00161	CcSEcCtD
Valsartan—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000344	0.00161	CcSEcCtD
Valsartan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000343	0.0016	CcSEcCtD
Valsartan—AGTR1—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	0.000342	0.00845	CbGpPWpGaD
Valsartan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00034	0.00159	CcSEcCtD
Valsartan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00159	CcSEcCtD
Valsartan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000339	0.00159	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—MPO—chronic obstructive pulmonary disease	0.000339	0.00838	CbGpPWpGaD
Valsartan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000338	0.00158	CcSEcCtD
Valsartan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000338	0.00158	CcSEcCtD
Valsartan—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00157	CcSEcCtD
Valsartan—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00157	CcSEcCtD
Valsartan—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000335	0.00827	CbGpPWpGaD
Valsartan—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000333	0.00156	CcSEcCtD
Valsartan—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000331	0.00155	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000327	0.00807	CbGpPWpGaD
Valsartan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00152	CcSEcCtD
Valsartan—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.00152	CcSEcCtD
Valsartan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.0015	CcSEcCtD
Valsartan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00032	0.0015	CcSEcCtD
Valsartan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00032	0.0015	CcSEcCtD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.000316	0.00781	CbGpPWpGaD
Valsartan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000314	0.00147	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000313	0.00774	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000313	0.00772	CbGpPWpGaD
Valsartan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000312	0.00146	CcSEcCtD
Valsartan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000312	0.00146	CcSEcCtD
Valsartan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000308	0.00144	CcSEcCtD
Valsartan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000308	0.00144	CcSEcCtD
Valsartan—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000307	0.00144	CcSEcCtD
Valsartan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000306	0.00143	CcSEcCtD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—chronic obstructive pulmonary disease	0.000303	0.00748	CbGpPWpGaD
Valsartan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.00141	CcSEcCtD
Valsartan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000301	0.00141	CcSEcCtD
Valsartan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00139	CcSEcCtD
Valsartan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00139	CcSEcCtD
Valsartan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00138	CcSEcCtD
Valsartan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000291	0.00136	CcSEcCtD
Valsartan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00136	CcSEcCtD
Valsartan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00134	CcSEcCtD
Valsartan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00134	CcSEcCtD
Valsartan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00132	CcSEcCtD
Valsartan—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000281	0.00132	CcSEcCtD
Valsartan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00131	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000281	0.00693	CbGpPWpGaD
Valsartan—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000277	0.0013	CcSEcCtD
Valsartan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00129	CcSEcCtD
Valsartan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00129	CcSEcCtD
Valsartan—ALB—Folate Metabolism—MPO—chronic obstructive pulmonary disease	0.000276	0.00682	CbGpPWpGaD
Valsartan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Valsartan—Rash—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Valsartan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Valsartan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Valsartan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00127	CcSEcCtD
Valsartan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00127	CcSEcCtD
Valsartan—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000272	0.00127	CcSEcCtD
Valsartan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00127	CcSEcCtD
Valsartan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00127	CcSEcCtD
Valsartan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00126	CcSEcCtD
Valsartan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00125	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000268	0.00662	CbGpPWpGaD
Valsartan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000267	0.00125	CcSEcCtD
Valsartan—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000264	0.00123	CcSEcCtD
Valsartan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00122	CcSEcCtD
Valsartan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.00121	CcSEcCtD
Valsartan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00121	CcSEcCtD
Valsartan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.00121	CcSEcCtD
Valsartan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00121	CcSEcCtD
Valsartan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000258	0.00121	CcSEcCtD
Valsartan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000258	0.00121	CcSEcCtD
Valsartan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.0012	CcSEcCtD
Valsartan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.00119	CcSEcCtD
Valsartan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000253	0.00118	CcSEcCtD
Valsartan—ALB—Platelet degranulation—SERPINA1—chronic obstructive pulmonary disease	0.000251	0.00621	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.00025	0.00618	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic obstructive pulmonary disease	0.000245	0.00605	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000244	0.00603	CbGpPWpGaD
Valsartan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00114	CcSEcCtD
Valsartan—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000242	0.00113	CcSEcCtD
Valsartan—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000241	0.00113	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SERPINA1—chronic obstructive pulmonary disease	0.000239	0.00591	CbGpPWpGaD
Valsartan—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000237	0.00111	CcSEcCtD
Valsartan—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.0011	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.0011	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000234	0.00579	CbGpPWpGaD
Valsartan—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000232	0.00108	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000231	0.0057	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00023	0.00569	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000227	0.0056	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000224	0.00553	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000219	0.00542	CbGpPWpGaD
Valsartan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00102	CcSEcCtD
Valsartan—ALB—Platelet degranulation—TGFB2—chronic obstructive pulmonary disease	0.000218	0.00538	CbGpPWpGaD
Valsartan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00102	CcSEcCtD
Valsartan—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000213	0.000996	CcSEcCtD
Valsartan—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000213	0.000995	CcSEcCtD
Valsartan—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000211	0.000989	CcSEcCtD
Valsartan—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000211	0.000986	CcSEcCtD
Valsartan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00098	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—chronic obstructive pulmonary disease	0.000207	0.00513	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000204	0.00504	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000204	0.00503	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000203	0.00501	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000199	0.00492	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000198	0.0049	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000198	0.0049	CbGpPWpGaD
Valsartan—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000924	CcSEcCtD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000196	0.00485	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000196	0.00484	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	0.000194	0.00479	CbGpPWpGaD
Valsartan—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000896	CcSEcCtD
Valsartan—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000881	CcSEcCtD
Valsartan—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000879	CcSEcCtD
Valsartan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.000875	CcSEcCtD
Valsartan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000861	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000182	0.0045	CbGpPWpGaD
Valsartan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000834	CcSEcCtD
Valsartan—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000834	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	0.000178	0.00441	CbGpPWpGaD
Valsartan—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000832	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000177	0.00438	CbGpPWpGaD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000177	0.000829	CcSEcCtD
Valsartan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.000811	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000171	0.0008	CcSEcCtD
Valsartan—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000171	0.0008	CcSEcCtD
Valsartan—Infection—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000795	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.00017	0.0042	CbGpPWpGaD
Valsartan—Shock—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000787	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000168	0.00415	CbGpPWpGaD
Valsartan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000784	CcSEcCtD
Valsartan—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000167	0.00413	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000167	0.00413	CbGpPWpGaD
Valsartan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000777	CcSEcCtD
Valsartan—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000763	CcSEcCtD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000161	0.00399	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00016	0.00396	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APIP—chronic obstructive pulmonary disease	0.000159	0.00394	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000729	CcSEcCtD
Valsartan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000728	CcSEcCtD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000155	0.00383	CbGpPWpGaD
Valsartan—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000724	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000718	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000153	0.00379	CbGpPWpGaD
Valsartan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000704	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.00015	0.00371	CbGpPWpGaD
Valsartan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000695	CcSEcCtD
Valsartan—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000694	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000693	CcSEcCtD
Valsartan—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000148	0.00069	CcSEcCtD
Valsartan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.00069	CcSEcCtD
Valsartan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000684	CcSEcCtD
Valsartan—ALB—Folate Metabolism—CRP—chronic obstructive pulmonary disease	0.000145	0.00359	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000145	0.00357	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000143	0.00353	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000143	0.00353	CbGpPWpGaD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000143	0.00353	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000654	CcSEcCtD
Valsartan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000654	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000137	0.00339	CbGpPWpGaD
Valsartan—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000635	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000632	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000131	0.00324	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00013	0.00321	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000128	0.00316	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000589	CcSEcCtD
Valsartan—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000574	CcSEcCtD
Valsartan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000566	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000121	0.00299	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000117	0.0029	CbGpPWpGaD
Valsartan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000547	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000115	0.00285	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000115	0.00285	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000114	0.00283	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000114	0.00282	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000114	0.00281	CbGpPWpGaD
Valsartan—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000529	CcSEcCtD
Valsartan—ALB—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000111	0.00275	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	0.000111	0.00275	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	0.000111	0.00275	CbGpPWpGaD
Valsartan—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000509	CcSEcCtD
Valsartan—Rash—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000504	CcSEcCtD
Valsartan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000504	CcSEcCtD
Valsartan—Headache—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000501	CcSEcCtD
Valsartan—SLCO1B1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000107	0.00265	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000106	0.00261	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00259	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000105	0.00259	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000103	0.00255	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GC—chronic obstructive pulmonary disease	0.000103	0.00254	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000102	0.00252	CbGpPWpGaD
Valsartan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000475	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000101	0.0025	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.0001	0.00247	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.0001	0.00247	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	9.68e-05	0.00239	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	9.66e-05	0.00239	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	9.56e-05	0.00236	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.55e-05	0.00236	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	9.11e-05	0.00225	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	9.06e-05	0.00224	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	8.86e-05	0.00219	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	8.86e-05	0.00219	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.57e-05	0.00212	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.45e-05	0.00209	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.19e-05	0.00202	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	8.11e-05	0.002	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	8.08e-05	0.002	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	8.01e-05	0.00198	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.67e-05	0.00189	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	7.64e-05	0.00189	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.61e-05	0.00188	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.25e-05	0.00179	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	7.23e-05	0.00179	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	7.19e-05	0.00178	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.15e-05	0.00177	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.1e-05	0.00175	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.05e-05	0.00174	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	7.04e-05	0.00174	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GC—chronic obstructive pulmonary disease	6.9e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	6.57e-05	0.00162	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	6.57e-05	0.00162	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.57e-05	0.00162	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.57e-05	0.00162	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	6.52e-05	0.00161	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	6.5e-05	0.00161	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.48e-05	0.0016	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.46e-05	0.0016	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.42e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	6.26e-05	0.00155	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.23e-05	0.00154	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.18e-05	0.00153	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	6.18e-05	0.00153	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	6.15e-05	0.00152	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.14e-05	0.00152	CbGpPWpGaD
Valsartan—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	6.12e-05	0.00151	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	6.03e-05	0.00149	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	5.87e-05	0.00145	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	5.79e-05	0.00143	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	5.75e-05	0.00142	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	5.74e-05	0.00142	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	5.65e-05	0.0014	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.61e-05	0.00139	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GCLC—chronic obstructive pulmonary disease	5.55e-05	0.00137	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.5e-05	0.00136	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	5.3e-05	0.00131	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	5.22e-05	0.00129	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.17e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.13e-05	0.00127	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	5.11e-05	0.00126	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CTGF—chronic obstructive pulmonary disease	5.06e-05	0.00125	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	5.01e-05	0.00124	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	4.98e-05	0.00123	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.92e-05	0.00122	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.66e-05	0.00115	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.52e-05	0.00112	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	4.47e-05	0.0011	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.36e-05	0.00108	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	4.24e-05	0.00105	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	4.21e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.2e-05	0.00104	CbGpPWpGaD
Valsartan—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.05e-05	0.001	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	4.03e-05	0.000995	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.02e-05	0.000993	CbGpPWpGaD
Valsartan—ALB—Metabolism—GC—chronic obstructive pulmonary disease	3.94e-05	0.000974	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.89e-05	0.000961	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.88e-05	0.000958	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.84e-05	0.000948	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.77e-05	0.000932	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	3.73e-05	0.000921	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.67e-05	0.000906	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.57e-05	0.000883	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.57e-05	0.000882	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.49e-05	0.000863	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.48e-05	0.000859	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.47e-05	0.000856	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	3.4e-05	0.00084	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.39e-05	0.000837	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.32e-05	0.00082	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.3e-05	0.000816	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.29e-05	0.000813	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	3.23e-05	0.000798	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.17e-05	0.000783	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.15e-05	0.000778	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.14e-05	0.000777	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.13e-05	0.000774	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.03e-05	0.000749	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3e-05	0.000741	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.92e-05	0.000722	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	2.92e-05	0.00072	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	2.88e-05	0.000711	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	2.82e-05	0.000698	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.82e-05	0.000696	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	2.68e-05	0.000661	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.61e-05	0.000646	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	2.6e-05	0.000641	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.58e-05	0.000637	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.4e-05	0.000593	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.39e-05	0.000591	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.32e-05	0.000573	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—chronic obstructive pulmonary disease	2.3e-05	0.000569	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.28e-05	0.000563	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.21e-05	0.000546	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—chronic obstructive pulmonary disease	2.2e-05	0.000544	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.19e-05	0.00054	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.15e-05	0.000532	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	2.13e-05	0.000526	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.11e-05	0.000522	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.09e-05	0.000515	CbGpPWpGaD
Valsartan—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	1.94e-05	0.00048	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.87e-05	0.000463	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.79e-05	0.000442	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.78e-05	0.00044	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.76e-05	0.000436	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.74e-05	0.000431	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.69e-05	0.000419	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.63e-05	0.000402	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.59e-05	0.000393	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—chronic obstructive pulmonary disease	1.55e-05	0.000382	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.52e-05	0.000376	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.5e-05	0.000371	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.49e-05	0.000369	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.48e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.47e-05	0.000364	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.47e-05	0.000362	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.4e-05	0.000345	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.38e-05	0.000341	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.37e-05	0.000339	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.37e-05	0.000338	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.000321	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.22e-05	0.000302	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.21e-05	0.000298	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.15e-05	0.000284	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	1.14e-05	0.000281	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.12e-05	0.000278	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.06e-05	0.000263	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.05e-05	0.00026	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	8.46e-06	0.000209	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	7.24e-06	0.000179	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	6.92e-06	0.000171	CbGpPWpGaD
